الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Liver biopsy is currently considered the gold standard in diagnosis of NAFLD& NASH, however it is an invasive technique & carries many risks. Serum Anandamide level is recently discovered to play an important role as potential indicator for NAFLD severity. Aim: Determining the association of eCB metabolite Anandamide (AEA) and NAFLD severity & investigate its association with anthropometric & metabolic features in NAFLD patients. Methodology: A case control study on 36 NAFLD biopsy proven NAFLD patients & 15 healthy volunteers. They were subjected to full clinical history & examination, laboratory tests, Abdominal ultrasound, & serological testing of Anadamide. Results: Anadamide level was significantly higher among NAFLD subgroups (SS & NASH) vs normal group (1.1, 0.29 vs 0.2 p value = 0.00085), with cutoff 0.58 in NASH group (accuracy 89%, sensitivity 66% & specificity 100%) (p value < 0.01), significantly related to BMI, T.cholesterol, FBG, MS (p value >0.05 , <0.05 , < 0.05 , 0.03 respectively) Conclusion: Anandamide could be a specific serum marker for NASH & can be used to detect NAFLD severity |